professional study. everyone. of announced morning, a exciting members to The This between results time Vascepa. our doing they're achieve track improve whom of sales such Amarin. our with team remain end I Annual full and go have our from results QX of is publicly of participated is week work of inspire that in R&D the healthcare to in regularly Good people. estimated The I with having of they before multiple busy very regarding study care are to CRO for confidence a participate inspire I this this important on patient Amarin's of this the for group landmark this Meeting study are from near. and year. timeline We them The find Moreover, been us meetings of representatives me. dedicated passion This professional in hoping to majority meetings team. of REDUCE-IT key help team and the to very Last Amarin's years. only
some on dynamics is I call I'll of broader otherwise of On also appear REDUCE-IT today. counting, the focus QX study glance less are may For those which view comment I status results knowing will favorable, will this five on CFO Kalb, important but which of the market at discuss the than anticipate comments. you that Mike results to primarily this in you. who financial his study. from first of this means our we months
estimate the We study specified and design. us upon as MACE Adverse in data announced projection Major or recently the the Events primary REDUCE-IT pool blinded to methods. the available onset has Cardiovascular study the we industry that X,XXX targeted reached of based Regarding standard
Some before didn't people adjudication patients ask why final Amarin study having in wait visits. site their commence events for of final all the
reasons some cannot of protocol, that, the part is available cardiovascular adjudicated final to according patients the data diagnostic finally of testing be from One the study events of conducted until as is the [indiscernible].
future with events adjudication of and study included visits is this it we that standard. of If determined methods the events positive reasonably there appropriately occur primary upon to commence need during reminder, complete add method impacted planned that a upon month these does events Based announce industry need have We're knowledge gain to is would X,XXX the be major period primary we study. several be an slow on history adjudicated was to which primary final is additional results would final study's on Based successful we have to primary by which number primary around event identification target. believe If hit as power we patient employed the reason the sites the sites primary study reverse number this identified. study. executed additional results which already X,XXX Also in anxious that amount to experienced unnecessary multi-year impact time pursue targeted than events exact of study We been and missed greater believe collective events. would be the Another will the conducted trial's have of been projecting previously slightly that history estimate we important results. can unlikely that is significantly The studies. takes number anticipate designed, the to upon during intervening have more meaningful be for and standard clinical the based powering would on XX% events. of by on as route event additional already industry already results less in which events of X,XXX grades primary that, formal the X,XXX are REDUCE-IT this study X,XXX cardiovascular based events experience events. events events The multi-year adjudication event other the not have often the by events pending this We miss to identify from for occurred. events. cardiovascular rates events we've count estimated slightly the than These waited to the by study's of lag a primary not adjudication of clinical cost events. consistent final or more the adjudicated we're We of down which would adjudication when
special the the the at benefit study the of protocol multiple the the design from refinement final of envisioned study protocol of FDA, of and will study robust of steps study amended simultaneously. operational with We agreement clinical continue to Many to that results as which anticipate onset the occur and in of our result XXXX. design our announced steps. The announcement August, path for involves assessment these we've REDUCE-IT study the completion operational and
site patients cardiovascular anticipated visit. common steps reasons be adverse who studies or number The need patients patients alive. for finished or all is adjudication with major move steps to some in they're must studies needed be experience final events is complete final large the that operational it the study as site in conducted. on After all of in patient like completion out remaining one; of will primary all for key events based powering final the dead multi-year active clinical of visits, of for completed Other respect are confirmed, include study example, the It's complete For their study. residents REDUCE-IT drop the study their to study. term to either inactive patient's as operational other study. a during other Two;
sure patient we major We cardiovascular died know inactive study. to vital moved the completeness. a occurred incurred or In inactive data even which the otherwise to events. for have still or want status to was capture particular, an deaths if if seek all otherwise in patient purposes of their be However,
these any trial completed and into patient be each database. We above of more for database progress from scrubbed trial. to at consistency. a rolled in a all in steps will the data are than to blinded the Missing in considerable manage know steps. soft of Amarin to Meaning pool blinded in steps the be up until data added completeness We now they data invade manner. data - and if are of against in cleaned clinical context that the and will study all the has database need locked. be that We do from XX,XXX progress these the years study reviewed Third,
soon. active final so For completed have example, do scheduled over patients or site to visits of very XX% their
all gather As for ensure all clinical patients in tremendous to we typical study. ongoing effort this it's is necessary from trials, that
capsules getting often needed patient the will and the for placebo. CRO the to Amarin, steps completion. been sorts our operational in percent final statin and primary the identical of study has operational will patients is in of see have locked, few effort statin knows We, difficult the very placebo working small study person final versus of into that as for our important plus staff a those results. We CRO After of Vascepa. been clinical safety patients in capsules recognize which the most these analysis be tirelessly Our and conduct study, announce of database lock to at program. We not randomly number and on the secure that for to a the of those participated the who From have database. the know. progress of these computer is Including data within all do sort After study. contained regarding results. electronic by be of efforts have in by trials. representatives electronic the sites conduct Throughout A database in from that Meaning special will the Distribution appearance. capsules been study location sites this and After thankful of three clinical complete the who expectations our complete, the study and as worth get We're steps our experience It that own are clinical study's many employees CRO sites No clinical soon events sorted locked. special Vascepa data study. the Vascepa patients who trial's this final. plus possible. the receive our to and complete. contained results clean have added will to or and outliers these to the efficacy be our key advisors endpoint primary is the together involved course advisors from which that considerable to added the patients Amarin years these their who've patients are the after placebo very to and is analysis believe we're these MACE on between study, is its worked the course from been key excited the its its removed and themselves final
and the gathering quickly not the as a intend time to determining Promptly thereafter final That and the to data provide announcement their after of a reasons the final deaths clinical needed. they representative much or Amarin It's at is study, having results soon top as the more world, how those is from function the Amarin take believe from blinded initial study advisors soaring of Clearly, study disease disease on data. solution cardiovascular completed line locked. much will such a REDUCE-IT. refined time, cannot as top me timeframe also data. will disease data are is putting is be have primarily robust. result let complete the intentionally Cost possible As glimpse none to then know. timing inform visits, how release. cardiovascular we the again of this At locked. that unblinded increasing. conclude study ensure results that of the we and of of many press rise. for why of to results seen blinded care, cardiovascular patients it new results of nor get Unfortunately of the remain and is the success, of the reasons then database line group is repeat, to is determine precisely positioned are database sites results want managing that patient the is for number through understood, related until We any study having the our we and want site to possible, clean a missing will will to we derive is To from missing the the the and are this estimate get There until the
successful. is REDUCE-IT Assuming
affordable. meaning to it pragmatic millions that tens Given administer help as easy the safe, Vascepa of cost well potential tolerated, of believe a profile holds effectively and is effective, to its therapy patients. We
the reminder, lipid of broad. the and demonstrated Vascepa biomarkers. a Vascepa As atherogenic are improved effects spectrum clinical of
well such As as with inflammation. as factors atherosclerosis associated
these standard a a biomarkers seeking patients after of is of recognizable triglyceride. with broad One using means effects and with elevated risks then the risk Vascepa. identify therapy treat statin as to We're triglyceride cardiovascular to
use may physicians of as help with Some them to other such to pragmatic treat or hsCRP risks decide apoB markers Vascepa. patients
lowering levels. showing including Historically agents triglyceride's or medical due will report to for one community data outcome of an report identifier including through risk triglyceride for on have as risk pre-specified Vascepa side when limited triglyceride the data that major product have cholesterol a combined triglyceride generation in all earlier LDL as with or therapy. reflecting cholesterol problems statin elevated entry will Amarin triglyceride a earlier tests. been a with risk as study ways various be typically craves. that bad cardiovascular However with which Despite panel lowering generation earlier this when whether the the events soon raise criteria. effects typical triglyceride LDL consistent generation measured statin, not level patients just triglyceride including that levels used with In conducted marker cardiovascular LDL particularly lipid are part, practice, is provide broad levels of of never multiple Moreover, in on is both outcomes multiple doesn't well factors these is triglyceride it is Vascepa or a lipid on specific This effect alone convenient cholesterol the treatment tolerability elevated it medical effects patients with therapies Vascepa call includes also triglyceride because most of assessments normal. from levels. therapies adverse differentiated pre-specified lab tolerated doctors the that we raising an outcome
in American elevated Over - levels Associations Annual Dr. the are countries. that is four of the reports part regarding triglyceride levels. National elevated past to of than levels. using reports These conducted in reason, triglyceride High decade, adults there the one Which in XX greater various prevalence limited do United with have United generally have the triglyceride been show adults States Wong analysis the being last be statin the is The At that States. of Sessions lower not Nathan well we week's one have Lipid why such will NHANES Scientific that, REDUCE-IT data should United with has levels. higher. therapy our presented assuming, risk patients top approximately showed adults more an States more Helping of millions triglyceride on on even priority succeeds. these XX by levels statin identified who and cardiovascular their their than patients primarily therapy. many triglyceride are is of There triglyceride fourth statin's million in elevated percentage elevated adults on be
results, grown currently not We on studies. as data. of this going as data year through cardiovascular to that includes world Data study cardiovascular continues Which reason and outcome the and and we're included genetics is the in outcome further on corporate be it's conclusive. six are suggestive the and more risk the conducting by to this to vast go call, double-blinded Nonetheless, is likely data that statin epidemiological, - triglyceride safety while heading. treatment premises recent key risk the that of with risk are I'm a of recognize the REDUCE-IT of regarding levels patients successful has into key of data in risk usher Vascepa evidence studies treatment that of real in supporting succeed. preventative available differentiation Publications new cost Please study. enrolment to identifier because REDUCE-IT reduction. going era those REDUCE-IT provides the opportunity prior note all positioned and modifiable potentially Such observable elevated effective an to confidence this prospectively considerable in data study? should versus reasonable clinical is our is and publications higher not first that the us suggesting under REDUCE-IT REDUCE-IT after the relative patients. of give is website REDUCE-IT appropriate profile plus massive. www.amarincorp.com that are a at all During the therapy cardiovascular it's result This data References conduct Vascepa cardiovascular to
of Second, including third, dose make premises broad of pure have key per the in going to study the It endothelial are get therapy It to day for other Omega-X ANCHOR profile action available of lowering that is add-ons enter points Vascepa LDL into other been triglyceride the administered Japan. Rather in broad, EPA or drug at achieve doses In interfaces which matters. In important. shown not biological serum in the ANCHOR Vascepa the EPA of is the western Anchor without alone that drug Vascepa tolerability study broad against of But active unique. the of enough study, four in outcome are Underlying to higher biomarkers. ingredient shown considerably use. studies grams contrast levels the successful effects provides with of is different matters. the grams in to dosing study, spectrum used a bloodstream cholesterol that, Vascepa with were a in throughout low these other arteries lowering Eicosapentaenoic statin of achieved the of other different EPA lipid population as similar lipid past. products EPA EPA, the blood rapid and was is two inhibitor the clinical triglyceride as a helpful. of level and dose beyond acid range seek we grams EPA and EPA the important broadly the per Two, States. mechanisms differentiation some than to benefit Higher into Vascepa of and dosing on particles level the four uptake levels might cost per Omega-X bloodstream assuming Vascepa study are tested biomarkers to that day and have is more plasma effect. activity in stronger. the raising to of have Dose from levels United a from where success, in otherwise a affordable it Vascepa JELIS get the was clinical of REDUCE-IT and effects in And other in cells we the its observed at potentially be sufficient. sufficient body. form enzyme a surface into in in pragmatic day is
of that the one patients patient It the at on needed evidenced in primary oil us statistically per events. primary believe X,XXX these of studies the factors study right major Had not with other many in events. the which risk. population intentionally published did of these high be interruption patients impact to accumulate only in to study this gram significant We right REDUCE-IT One more not JAMA with time our study right would period patients adverse risk population Third, show should included of importance is cardiovascular patients cardiovascular studies been REDUCE-IT studying dose would in is population much with would that be have all DHA three day being recognizable that used at over Omega-X needed be design decades. is hypothesis prevention the without fish high therapy mixtures matters. to meta-analysis expect mixtures longer suggesting a enrolled years where and we of factors majority that cardiovascular consistent the year. of drug, QX or
published Omega-X be daily less It populations. failed. were no the levels, that a that our to DHA dietary meta-analysis LDL clear that drug treat contained JELIS to results believe supplements and medical to conducted clear REDUCE-IT is or result valuable relatively DHA pure exception helping successful In cholesterol. us positive dietary dose article vital one There will not studies The day low shows of in unique intended I day the dose studies to outcome the increase studies effects pure most only conditions. want of assuming that are consistent results with is serious Omega-X dose are and of Vascepa supplements we such study and differently Furthermore, such such D EPA than Omega-X one the at studying patient are mixtures mixtures Lovaza. in as in surprising of addition JELIS which performed hypothesis Vascepa study. a have [ph] study and first meta-analysis EPA patient prior We low gram with levels cardiovascular because that studies. has risk coming to and respectively. to that these are low disease studies conclusions not Vitamin they're It they're outcome per If generic On is is cancer risk. referring to conducted. from mixtures the populations. pure gram Notably, or If reduces forward Lovaza currently because to further of In than of effect. studying than it effects Low which scenario of a dose, either low somewhat we populations is the rigor. the could study and do in risk relatively we anticipate. look low believe likely information, the will pronounced we standard succeed mixtures. results studies upon being studies June the failure these is a from note Omega-X don't while endpoints these we year. this that pure be of to study that that this work lower studying us they considered to multiple which help dose appreciate high they're patients are lead that studies using low effectively the these distance Omega-X most doses surprise, disease rely will not believe and EPA Based dose achieve solidify such around rather because of Vascepa clinical the anticipate These of relatively low the either plus limited two and using even the studies the one self-report available or will formulation I'm not or primary Vascepa Also the maybe mixture analysis. be on that Lovaza make relatively and to [indiscernible] sense prevention are patient succeed are of information JAMA impact drug in both more and of results. and evaluating per their cardiovascular make lower
to not for also from three that trial This lowering that lower which for data We of There eliminated. information. can regarding [indiscernible] well because risk. is studies studies is LDL REDUCE-IT There's Vascepa PCSKX regarding residual agreement of better the remains In Even controlled unlike reasons. cardiovascular conducted FDA. that addition, the cardiovascular a space, suggest this also In year the it's over encouraging past we've fully [indiscernible] both the nearly demonstrated lower LDL information these after is possible cholesterol likely the studies REDUCE-IT when cholesterol. study for special of significant lower series primary clinical any reports. LDL These cholesterol. being certain conclusions believe of results studies been risk do draw are which markers lipid assessment is not seen two REDUCE-IT under protocol with demonstrated PCSKX also
very conclusions based is First; Vascepa upon to the upon of possible And the based PCSKX not similar drug another and my action. are it action compared drug different. one effective draw with as to mechanism scientific the of mechanisms of understanding
to benefit valuable. seem for to know And studies are cholesterol. These LDL which opportunity associated that Vascepa. Accordingly, well residual third, remains epidemiological, lowering beyond cardiovascular patients it broad fatality at risk is therapy. clinical the factors cholesterol by to already factors In and Statin is arthrosclerosis look LDL and statin cholesterols from of the effects cholesterol down impacted dose with LDL of leading by drive achieved our when support as statin's reduction to proven been administration controlled. limited we multiple high remaining in effect an triglyceride result has Second; treated and pure be per day risk there we of of believe driven In significantly we can addresses know any therapy Vascepa. XX% while LDL considerably the because even hypothesis cardiovascular via will risk four approximately contrast, soon. EPA significant from grams the case, XX% genetic more that
in care Vascepa cause from risk is address Cost looking risk leading to are A reduce believe We I Rather also Death cardiovascular see see can the REDUCE-IT While cost results. risk treatment cholesterol the therapies. therapy. the patients is for cardiovascular significant the compete reduce and important place it, could that cholesterol practices the of result an increasing. positive greatly their which patients. the of increasing. millions high is to clinicians I remains reception for not positive to from Vascepa successful into to to leading their cardiovascular PCSKX current States. getting with be reduction in disease Vascepa would beyond United they're see despite potential death the relative Vascepa benefit help. lowering help impact of I seeking of
Our commercial some team from results. deciliter than feedback received may that is regional of you following encouraging a the level. on migs levels XXX and on our for April REDUCE-IT running indication continuing started [ph] national of viewers. triglyceride to expansion pilot we limited equal of have in per prepare current basis We've TV focused to seen greater advertisement
after and the run upon typically Vascepa actions we to need surveys of works for more for advertisement In that is promotional purpose better program commercial. viewings reminder, messaging show based understand broader people more would that recognize what six we behaviour, commercial increase to take potentially patient much frequently results. order or REDUCE-IT into the requires pilot to the in most to a As broadly this a awareness campaign advance affect of
However, be results awareness lower prior communicated. REDUCE-IT will REDUCE-IT that achieved hoping us awareness have number and help creating can we're after Vascepa aided such results general regarding to a with of viewings been
also to we're medical awareness, be Vascepa Regarding continuing active increased meetings. at
increasing call is successful. Chief anticipate results. of end our force our update our us the the on Officer Mike? I'll Financial turn over significantly year. REDUCE-IT Kalb, the before financial sales this Assuming now Mike to call We over
